COMMUNIQUÉS West-GlobeNewswire

Philips and Mass General Brigham announce collaboration to improve patient care with live AI-powered insights
21/02/2025
February 21, 2025 Integrating advanced data analytics into clinical practice to improve patient care Amsterdam, The Netherlands and Cambridge, MA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health [...]
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
20/02/2025
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its [...]
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025
20/02/2025
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
NewGen Issues Clarification on Press Release Titled “NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” dated February 20, 2025
20/02/2025
BANGKOK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today issued a clarification that, in the press release titled “NewGen Receives Continued Nasdaq Listing [...]
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
20/02/2025
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by [...]
Brighter Strides ABA Expands Services with New Clinic Opening in Maryland
20/02/2025
Providing Compassionate, Individualized ABA Therapy for Children with Autism Catonsville, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Brighter Strides ABA is proud to announce the grand opening of its newest clinic in [...]
AMN Healthcare Announces Fourth Quarter and Full Year 2024 Results
20/02/2025
Quarterly revenue of $735 million; GAAP loss of ($4.90)/share and adjusted EPS of $0.75 DALLAS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent [...]
Globus Medical Reports Fourth Quarter and Full Year 2024 Results
20/02/2025
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, [...]
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
20/02/2025
PMD-026 is a first-in-class and best-in-class pan-RSK inhibitor Favorable mPFS demonstrated in Phase 1/1b as a monotherapy in RSK2-high metastatic breast cancer patients. SAN DIEGO and VANCOUVER, British Columbia, Feb. [...]
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
20/02/2025
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20/02/2025
DUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of [...]
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025
20/02/2025
SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and [...]
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
20/02/2025
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual [...]
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
20/02/2025
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company [...]
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
20/02/2025
MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the [...]
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
20/02/2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
20/02/2025
HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
20/02/2025
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN [...]
Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders
20/02/2025
BALTIMORE, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on treating rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has [...]

Pages